Compare Davita Inc (DVA) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Garmin Ltd. — how do they compare? Davita Inc trades at $230.55 (market cap $14.92B), while Garmin Ltd. trades at $242.98 (market cap $46.55B). The key difference: Garmin Ltd. is far larger — about 3.1× Davita Inc's market cap, and Garmin Ltd. pays a 1.74% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | GRMN | |
|---|---|---|
Market Cap | $14.92B | $46.55B |
Sector | Health | Technology |
52-Week High | $235.71 | $267.52 |
52-Week Low | $103.87 | $187.10 |
Enterprise Value | $27.47B | $44.02B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Garmin (GRMN) trades at $243.61, up 0.21% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $7.25B in 2025, with a net income margin of 23.26%. Recent product launches, including AXIS flight displays and LiveScope 2 sonar, highlight innovation. The stock is near its pivot point of $243, with support at $242 and resistance at $245.
Outlook remains positive with a consensus price target of $282.67, implying 16% upside. Risks include competitive pressures in consumer electronics and aviation markets. Analyst sentiment is mixed, with 74% hold ratings, but earnings beats in recent quarters support growth trajectory. Dividend payments provide shareholder returns, with the next payment scheduled for September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
